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Abstract
Background: Encapsulating peritoneal sclerosis (EPS) commonly presents after peritoneal dialysis has been stopped, either
post-transplantation (PT-EPS) or after switching to hemodialysis (classical EPS, cEPS). The aim of the present study was to
investigate whether PT-EPS and cEPS differ in morphology and clinical course.
Methods: In this European multicenter study we included fifty-six EPS patients, retrospectively paired-matched for
peritoneal dialysis (PD) duration. Twenty-eight patients developed EPS after renal transplantation, whereas the other
twenty-eight patients were classical EPS patients. Demographic data, PD details, and course of disease were documented.
Peritoneal biopsies of all patients were investigated using histological criteria.
Results: Eighteen patients from the Netherlands and thirty-eight patients from Germany were included. Time on PD was
78(64–95) in the PT-EPS and 72(50–89) months in the cEPS group (p.0.05). There were no significant differences between
the morphological findings of cEPS and PT-EPS. Podoplanin positive cells were a prominent feature in both groups, but with
a similar distribution of the podoplanin patterns. Time between cessation of PD to the clinical diagnosis of EPS was
significantly shorter in the PT-EPS group as compared to cEPS (4(2–9) months versus 23(7–24) months, p,0.001). Peritonitis
rate was significantly higher in cEPS.
Conclusions: In peritoneal biopsies PT-EPS and cEPS are not distinguishable by histomorphology and immunohistochem-
istry, which argues against different entities. The critical phase for PT-EPS is during the first year after transplantation and
therefore earlier after PD cessation then in cEPS.
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Introduction
Prolonged time on peritoneal dialysis (PD) could be complicated
by encapsulating peritoneal sclerosis (EPS), a rare but severe
complication [1–6]. Nowadays, three diagnostic hallmarks are
used, i.e. clinical symptoms, radiologic findings and macroscopi-
cal/histological criteria [7–9]. In 2000, the International Society
for Peritoneal Dialysis (ISPD) defined EPS by clinical signs of
abdominal pain, bowel obstruction or weight loss in late stages of
the disease [10]. Vlijm et al. [11] and Tarzi et al. [12] published
computed tomography (CT)-based scores to diagnose EPS by
radiological findings. Several working groups studied histological
findings in EPS. However, diagnostic criteria are not well defined
[13–15]. Recently, we established a scoring system based on
morphological and immunohistochemical features [8]. This study
was performed to distinguish simple sclerosis from EPS, more than
20 histological findings were studied and described.
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Several risk factors for development of EPS have been reported.
The risk of EPS increases with longer time on PD. Additionally
younger age, glucose load, peritonitis rate, and cessation of PD are
factors illustrated in some studies [5,16,17]. EPS may occur when
patients are on dialysis (classical EPS, cEPS) or after undergoing a
kidney transplantation (post-transplantation EPS, PT-EPS). The
prevalence of PT-EPS has been reported to be between 1 and 3%.
This presentation of EPS seems to occur shortly after kidney
transplantation in former PD patients [18–21].
The pathophysiology of EPS is still unknown. The widely
discussed second-hit theory assumes that the peritoneal membrane
is ‘‘preconditioned’’ by the prolonged use of dialysis fluids resulting
in a repair process with inflammation and fibrosis, so called simple
fibrosis [21–23]. When the second-hit occurs, for example an
inflammatory stimulus like bacterial peritonitis, or discontinuation
of PD, EPS can develop [24]. There are several hypotheses how
transplantation might act as a ‘‘second-hit’’. These include
discontinuation of peritoneal lavage of proinflammatory factors,
direct apposition of damaged peritoneal membrane or, after
successful kidney transplantation, concomitant use of profibrotic
calcineurin inhibitors (CNIs) [7,20,21,25]. Previously, Khanna et
al. showed that both, Ciclosporine and Tacrolimus can enhance
TGB-ß expression and subsequent fibrosis [26].
From a clinical point of view, both cEPS and PT-EPS are
similar with regard to clinical presentation and radiological
findings. However, post-transplantation EPS seems to be associ-
ated with less systemic inflammation at time of presentation and a
better outcome [19,21]. The purpose of the current analysis was to
determine whether the morphological features of patients
presenting with PT-EPS are different to cEPS, thus suggesting a
different clinical entity. The clinical course following cessation of
PD is also compared. For this purpose we combined peritoneal
biopsies from two countries of an European consortium [7].
Materials and Methods
Study population
In the present study, 56 peritoneal biopsies were studied. All
biopsies (n = 9) of PT-EPS cases in the biobank of the Dutch EPS
registry and Rotterdam PA database (Netherlands) were selected
and for each PT-EPS biopsy, one biopsy of a cEPS case was
selected resulting in a total number of 18 biopsies [3]. Likewise, a
total number of 38 biopsies (including 19 PT-EPS biopsies and 19
cEPS biopsies) were selected from the biobank of the Robert Bosch
Hospital in Stuttgart (Germany).
In total, 28 biopsies from patients with PT-EPS were included in
the present study. PT-EPS was defined as EPS in former PD
patients undergoing a kidney transplantation, after which they
developed EPS while having a functioning renal allograft. All 28
biopsies of cEPS patients were paired-matched for PD duration.
After cessation of PD, none of the patients performed peritoneal
lavage. Classical EPS was defined as EPS in patients who had been
or were treated with PD without undergoing prior kidney
transplantation.
For the diagnosis of EPS we used clinical criteria stated by
Nakamoto et al. [27], radiological criteria by Vlijm et al. [11] and
histological criteria by Braun and Honda et al [13,28].
Data collection included demographic data, PD details at start
of dialysis. The study protocol was approved by the medical ethics
committee of Erasmus Medical Center and by the local ethics
committee in Germany (#322/2009BO1, Eberhard-Karls Uni-
versity Tuebingen, Germany). All patients gave written informed
consent before participating in the study.
Peritoneal biopsies and analysis
Biopsies from the visceral peritoneum were formalin-fixed in
4% buffered formalin and paraffin-embedded following routine
protocols [29]. All peritoneal biopsies were taken from patients at
the time of catheter removal or during abdominal surgery (e.g.
enterolysis, peritonectomy and enterolysis (PEEL)) following the
protocol published by Williams et al. [30] in the time period from
February 2002 to December 2012. Staining for podoplanin with
the monoclonal antibody D2-40 has been used in several previous
studies demonstrating the expression and pattern in EPS [8,28,31].
A monoclonal mouse antihuman podoplanin antibody (D2-40,
DAKO, Baar, Switzerland) was used on all biopsies [8,32]. A
negative control specimen was created by omitting the primary
antibody. Podoplanin was evaluated as either vascular or
podoplanin avascular (0, 1, 2, 3). Furthermore, the histological
description and pattern(s) of podoplanin-positive cells in peritoneal
biopsies were investigated. The biopsies were separated into four
groups (‘‘low’’ podoplanin pattern, ‘‘organized’’ pattern, ‘‘diffuse’’
pattern and ‘‘mixed’’ pattern with features of both ‘‘organized’’
and ‘‘diffuse’’ patterns) [31].
From each slide hematoxylin and eosin staining was done for
morphological analysis as previously described [8]: fibrosis:
absent, 1–10%/low-power field (LPF), 11–50%/LPF, .51%/
LPF (0, 1, 2, 3). Fibroblast-like cells (FLC): absent, 1/5 high-
power fields (HPFs), 2–4/5 HPFs, .5/5 HPFs (0, 1, 2, 3);
exudation: absent, 1 small area in 1 MPF, 1 area ,50%/MPF,
1 area .50%/medium-power field (MPF) (0, 1, 2, 3); cellularity
was evaluated as 0(1–2 nuclei/HPF), 1(3–5 nuclei/HPF) 2(6–20
nuclei/HPF) and 3(.20 nuclei/HPF); vessel density: absent, 1–
5/HPF, 6–10/HPF, .10/HPF in the submesothelial cell layer
(0, 1, 2, 3), acute inflammation (neutrophiles): absent, 1/HPF,
2–5/HPF, .5/HPF (0, 1, 2, 3); chronic inflammation (round
cells): absent, 1–5/HPF, 6–20/HPF, .20/HPF (0, 1, 2, 3);
hemorrhage: absent extravasal erythrocytes, 1 area ,10%/5
LPF, 2+3 area/5 LPF or 1 area 11–30%/LPF, 4+5 area/5 LPF
or 1 area .30%/LPF (0, 1, 2, 3); fibrin deposits: absent
eosinophilic area, 1 area ,5%/5 MPF, 1 area 6–20%/5 MPF, 1
area .20%/5 MPF (0, 1, 2, 3); presence of vasculopathy:
thickening of vessel walls and/or inflammation of the vessel wall
(0, 1); mesothelial denudation: no visible mesothelium (0, 1);
presence of acellular areas (0, 1); presence of brown, probably
iron deposits (0, 1); presence of blue, probably calcium deposits
(0, 1), and osseous metaplasia (0, 1). FLC were defined as
elongated cells, separated from vessel lumen with vesicular
nucleus and one to three nucleoli. Acute inflammatory reaction
was defined by the presence of neutrophilic granulocytes.
Chronic inflammatory reaction was defined by the presence of
round cells without taking into consideration further subclasses
such as lymphocytes, plasma cells, monocytes and histiocytes.
Furthermore thickness of the sub mesothelial cell (SMC) zone
was measured as was descripted previously [30,33,34].
HPF= 0.26 mm2, MPF= 0.91 mm2, LPF = 3.2 mm2. Two ex-
perienced observer (one pathologist and one nephrologist)
blinded to the specimen’s diagnosis evaluated each section.
Statistical analysis
Continuous data are expressed as mean 6 standard deviation
(SD). Variables were classified as either binary (present or
absent) or ordinal. The ordinal variables were discriminated as
absent, low grade, moderate grade and high grade. We
compared a four level classification system with a two level
classification system. Each parameter was analyzed for its inter-
observer variability. Comparisons between different disease
groups were made using analysis of variances (ANOVA) and the
Post-Transplantation and Classical EPS
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Fisher-test. Statistical results with a p-value#0.05 were consid-
ered as statistically significant.
Results
The baseline clinical characteristics of the study population
are shown in table 1. A total of 56 EPS patients were included
(28 PT-EPS and 28 cEPS patients, Figure 1). Eighteen patients
from the Netherlands and thirty-eight patients from Germany
were included. Time on PD was 78(64–95) months in the PT-
EPS and 72(50–89) months in the cEPS group without a
significant difference between the groups, indicating successful
matching. In both groups, there were more female than male
(p.0.05). Patients with cEPS demonstrated a significant higher
rate of peritonitis episodes (most common organisms were
Staphylococcus aureus followed by coagulase negative Staphylo-
cocci in both groups) and a more frequent use of Icodextrin
(table 1).
The time between cessation of PD and diagnosis of EPS was
significantly longer in cEPS compared to time after transplan-
tation in PT-EPS group (23(7–24) months vs. 4(2–9) months, p,
0.001) (table 1 and figure 1). Time from onset of symptoms
associated with EPS to requirement of surgery was 8(5–11)
months in the PT-EPS and 5(4–8) months in the cEPS group
Figure 1. Schematic course of the studied patients. Fifty-six patients started PD. After a mean of approximately six years, twenty-eight patients
were transferred to HD, whereas the other twenty-eight patients received a functioning renal allograft. Peritonitis rate was higher and the use of
Icodextrin more common in the cEPS compared to the PT-EPS group. Time between transfer to hemodialysis and development of EPS was
significantly longer, compared to time between transplantation and development of EPS (23(7–24) months vs. 4(2–9) months, p,0.001; cEPS classical
EPS, PT-EPS post-transplantation EPS).
doi:10.1371/journal.pone.0106511.g001
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(p = 0.7). Other parameters including outcome were not
significantly different between the groups. All patients in the
PT-EPS group were treated with CNIs as part of the transplant
immunosuppressive protocol. Six out of twenty-eight patients in
the PT-EPS group were exposed to both, Ciclosporin and
Tacrolimus.
Table 1. Clinical data of PT-EPS and cEPS patients; PD, peritoneal dialysis; EPS, encapsulating peritoneal sclerosis; PET, peritoneal
equilibrium test, PDF, peritoneal dialysis fluid, *p,0.05, **p,0.001, #median and interquartile range.
Variable Post-transplantation EPS Classical EPS
N 28 28
Age (years)# 52 (46–58) 55 (52–63)
Female/Male 17/11 21/7
CT diagnostic 28 28
Peritoneal thickening 13 12
Bowel dilatation 15 16
Calcification 7 9
Ascites 19 14
Clinical features
Bowel obstruction
Nausea and vomiting 23 22
Loss of appetite 18 15
Abdominal pain 28 26
Diarrhea 9 10
Inflammation
Fever 10 7
PD details
PD-duration at time of EPS diagnosis in months# 78 (64–95) 72 (50–89)
PET (switch to HD/NTx) 21 22
Low/low average 7 5
High average/high 14 17
Composition of PDF
Neutral pH 6 10
Acidic pH 11 11
Both 8 3
N.D. 3 4
Icodextrin* 13/24 22/25
Peritonitis* 45 in 1990 months 1:44.2 103 in 1913 months 1:18.6
No peritonitis episodes 8/28 3/28
1–4 peritonitis episodes 19/28 17/28
.4 peritonitis episodes 1/28 8/28
Reason for cessation PD
Peritonitis 10
Ultrafiltration failure 13
Technical failure 5
Age at time of NTx# 39 (32–47)
Transfer to HD or NTx to diagnosis EPS (months)**# 4 (2–9) 23 (7–24)
Treatment after transplantation
Tacrolimus 13
Ciclosporin 9
Both 6
Follow-up
Follow-up time (months)# 29 (22–74) months 31 (20–63) months
Alive/Dead 19/9 14/14
doi:10.1371/journal.pone.0106511.t001
Post-Transplantation and Classical EPS
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A detailed evaluation of the biopsies from 28 PT-EPS patients
and of 28 patients with cEPS was performed (Table 2, Figure 2).
Two observer blinded to the diagnosis studied the slides. Examples
of the 17 parameters were illustrated in figure 2. As previously
described the majority of EPS biopsies demonstrated severe
fibrosis, accumulation of fibroblast like cells, mesothelial denuda-
tion, fibrin deposits and chronic inflammation (Table 2). The
degree of fibrosis was measured and additionally analyzed
semiquantitatively. Measurement of fibrosis revealed a fibrosis
zone of 1369 mm [IQR 946–2551] in cEPS and 1690 mm [IQR
1356–2598] in PT-EPS (p = 0.17). Furthermore, podoplanin
positive cells and podoplanin positive lymphatic vessels were
prominent features (Figure 2).
Based on the morphological evaluation the biopsies with PT-
EPS could not be separated from cEPS (Figure 2). There was no
significant difference in any of the scored parameters (Table 2).
The prominent staining for podoplanin in EPS biopsies was seen
to be identical in both country sources, reproducing previous
findings. The scores for podoplanin were not significantly
different. The peritoneal biopsies were separated into four groups:
‘‘low’’ podoplanin pattern, ‘‘organized’’ podoplanin pattern,
‘‘diffuse’’ pattern and ‘‘mixed’’ pattern with features of both
‘‘organized’’ and ‘‘diffuse’’ patterns). Using this detailed analysis,
no differences could be detected between the PT-EPS and cEPS
group (all p.0.05) (table 3). Importantly, the percentages of the
various patterns were similar as previously described [31].
To avoid a systematic bias between the peritoneal biopsies from
different sources (i.e. the Netherlands and Germany), the results
were compared between the biopsies from different countries.
There was no statistically significant difference between the
peritoneal biopsies from the German patient cohort compared to
the patients from the Netherlands (table 4).
Discussion
Previous studies suggest, that the clinical course of cEPS differs
from patients who develop EPS after transplantation. Therefore,
the goal of this study was to compare the morphology of a high
number of peritoneal biopsies from patients with PT-EPS and
cEPS to detect possible histological differences between the two
groups. We matched the groups according to ‘‘time on PD’’, the
most relevant risk factor for the development of EPS. A separation
of the two groups on morphological grounds would provide
evidence that these reflect two different pathological entities.
Inflammation, angiogenesis and fibrosis are the main features of
EPS, resulting in exudations of fibrin and chronic inflammation of
the peritoneal membrane [35]. This leads to adhesions, develop-
ment of a fibrous cocoon covering the intestines and results in
symptoms of bowel obstruction [10,36]. The biopsies included in
our study demonstrated the typical (but non-specific) morpholog-
ical features described for EPS. We could not confirm the
hypothesis that PT-EPS and cEPS are two different entities, as the
Table 2. Histological findings in patients with post-transplantation EPS and classical EPS; Fibrosis (0, 1 vs. 2, 3), Fibroblast-like-cells
(FLC) (0, 1 vs. 2, 3), Exudation (0, 1 vs. 2, 3), Mesothelial denudation (0 vs. 1), Acellular areas (0 vs. 1), Cellularity (0, 1 vs. 2, 3), Vessel
density (0, 1 vs. 2, 3), Acute inflammation (0, 1 vs. 2, 3), Chronic inflammation (0, 1 vs. 2, 3), Vasculopathy (0 vs. 1), Hemorrhage (0, 1
vs. 2, 3), Fibrin deposits (0, 1 vs. 2, 3), Calcification (0 vs. 1), Iron deposits (0 vs. 1), Ossification (0 vs. 1), Podoplanin vascular (0, 1 vs.
2, 3), Podoplanin avscular (0, 1 vs. 2, 3).
Variable PT-EPS (n =28) cEPS (n =28) p
Fibrosis 1/27 2/26 1
FLC 14/14 10/18 0.4
Exudation 12/16 14/14 0.8
Mesothelial denudation 0/28 0/28 1
Acellular areas 16/12 21/7 0.3
Cellularity 12/16 8/20 0.4
Vessel density 9/19 5/23 0.4
Acute inflammation 24/4 23/5 0.3
Chronic inflammation 16/12 13/15 1
Vasculopathy 5/23 6/22 1
Hemorrhage 17/11 15/13 0.8
Fibrin deposits 11/17 10/18 1
Calcification 25/3 26/2 1
Iron deposits 11/17 10/18 1
Ossification 0/0 0/0 1
Podoplanin vascular 16/12 17/11 1
Podoplanin avascular 11/17 10/18 1
doi:10.1371/journal.pone.0106511.t002
Figure 2. Morphologogical evaluation of peritoneal biopsies in PT-EPS and cEPS. Peritoneal biopsies were either stained with PAS (A, B, E–
H) or by immunohistochemistry with a monoclonal antibody against podoplanin (D2-40, C, D, original magnifications X 400 in A–D, G, H, X200 in E, F).
The morphological evaluation demonstrated similar degrees of denodation and fibrin deposition (A, B), podoplanin positive cells (C, D), fibrosis (E, F)
and acellular ares (G, H). (left column post transplant EPS; PT-EPS, right column classical EPS, cEPS).
doi:10.1371/journal.pone.0106511.g002
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histological evaluation could not separate biopsies from the
groups. Although, we applied all ever published histological
features in EPS, we found no significant differences between the
two groups [8]. Immunohistochemstry with podoplanin, including
an extensive pattern analysis revealed no difference between the
groups. Recently, Kinashi et al. showed that peritoneal tissue from
patients with ultrafiltration failure (UFF) contained more lym-
phatic vessels than tissue from patients without UFF [37].
Podoplanin was found to be a good marker for lymphatic
endothelial cells, but is expressed by peritoneal mesothelial and
fibroblast-like-cells (FLC) too [8,38]. In our patient cohort,
approximately fifty-percent of the patients in both groups showed
a strong expression of podoplanin, but no difference in the
expression pattern. Hence, podoplanin seems to play an role in the
pathogenesis of EPS, but does not differentiate between cEPS and
PT-EPS.
The incidence of EPS increases with time on PD (other factors
like peritonitis rate, male gender, younger age, smoking and
glucose exposure are under debate) [5,16,32,39–44]. The group of
patients with cEPS demonstrated a higher-rate of peritonitis, and
the use of icodextrin was more common, whereas the time to
diagnosis after cessation of PD was longer in the cEPS group. The
shorter time to clinically symptomatic EPS in patients after kidney
transplantation has previously been described [21,45]. Interest-
ingly, there were no differences regarding morphological findings,
and particularly no differences in the severity of fibrosis, using
both, semi-quantitative and quantitative analysis. This could argue
that factors in the PT-EPS group resulted in a faster progression of
the disease. It is likely that the time to the clinical manifestation is
based on the ratio of pro fibrotic factors (e.g. time on PD, surgery,
peritonitis, calcineurin-inhibitors) and factors which might inhibit
the disease process (e.g. steroids, rinsing the abdominal cavity).
The combination of pro-fibrotic factors after transplantation might
result in a faster disease process, although the major players in the
pathogenesis have not been defined [21].
It has been recently shown in a rat model of peritoneal exposure
to dialysis fluid that additional administration of Ciclosporin leads
to EPS like abnormalities [46]. The calcineurin-inhibitors
Table 3. Podoplanin patterns [31] in post-transplantation and classical EPS patients; Organized pattern (0 vs. 1), Diffuse pattern (0
vs. 1), Low pattern (0 vs. 1), Mixed pattern (0 vs. 1).
Variable Post-transplantation EPS (n=28) Classical EPS (n =28) p
Organized pattern 10 8 0.8
Diffuse pattern 7 6 1
Low pattern 1 5 0.2
Mixed pattern 4 4 1
doi:10.1371/journal.pone.0106511.t003
Table 4. Histological findings in patients with EPS (post-transplantation EPS and classical EPS) in the study population of the
Netherlands and Germany; Fibrosis (0, 1 vs. 2, 3), Fibroblast-like-cells (FLC) (0, 1 vs. 2, 3), Exudation (0, 1 vs. 2, 3), Mesothelial
denudation (0 vs. 1), Acellular areas (0 vs. 1), Cellularity (0, 1 vs. 2, 3), Vessel density (0, 1 vs. 2, 3), Acute inflammation (0, 1 vs. 2, 3),
Chronic inflammation (0, 1 vs. 2, 3), Vasculopathy (0 vs. 1), Hemorrhage (0, 1 vs. 2, 3), Fibrin deposits (0, 1 vs. 2, 3), Calcification (0 vs.
1), Iron deposits (0 vs. 1), Ossification (0 vs. 1), Podoplanin vascular (0, 1 vs. 2, 3), Podoplanin avscular (0, 1 vs. 2, 3).
Variable Netherlands (n =18) Germany (n=38) p
Fibrosis 2/16 1/37 0.2
FLC 10/8 14/24 0.3
Exudation 8/10 18/20 1
Mesothelial denudation 0/18 0/38 0.3
Acellular areas 13/5 24/14 0.6
Cellularity 6/12 14/24 1
Vessel density 3/15 11/38 0.5
Acute inflammation 14/4 33/5 0.4
Chronic inflammation 11/7 18/20 0.4
Vasculopathy 5/13 6/32 0.3
Hemorrhage 12/6 20/18 0.8
Fibrin deposits 9/9 12/26 0.2
Calcification 18/0 33/5 0.2
Iron deposits 4/14 17/21 0.1
Ossification 0/0 0/0 1
Podoplanin vascular 13/5 20/18 0.2
Podoplanin avascular 9/9 12/26 0.2
doi:10.1371/journal.pone.0106511.t004
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(Ciclopsorin and Tacrolimus) can lead to enhanced expression of
transforming growth factor-b (TGF-b), demonstrated in a
preconditioned peritoneal membrane, which already demonstrat-
ed up-regulation of TGF-b. This results in increasing fibrosis and
neoangiogenesis of the peritoneal membrane [21,26,47]. Due to
the lack of biopsies at the time of transfer to either dialysis or
transplantation we cannot prove the differences in progression. It
is less likely that PT-EPS patients would have had more severe
membrane injury at the time of modality transfer compared to the
cEPS group who likely had complications leading to technique
failure as evidenced by their higher rate of peritonitis episodes and
greater need of Icodextrin, suggesting either UFF or less residual
renal function. This raises an important question: could the
morphological evaluation at the time of transfer to a different form
of renal replacement therapy add value to an overall risk
assessment (including time on treatment, peritonitis history and
ultrafiltration failure) in predicting the development of EPS? This
requires a high number of patients with biopsies at transfer when
removing the PD catheter, and we will try to answer this question
within the European patient cohort in the future.
An alternative explanation for the differences between the time
to manifestation would be that patients after transplantation might
be seen more often in the transplant clinics and/or symptoms
might rather be ignored in patients on hemodialysis, as had been
reported by patients [48]. In 9 interviews of patients with EPS the
patients described a loss of trust in the doctors as symptoms while
being on dialysis were not taken seriously [48].
If patients after transplantation would be detected earlier in the
diseases course due to more frequent doctor visits, it would be
expected that the histological finding would be less extensive in
patients with PT-EPS. Particularly, the fibrosis scores should be
less severe, but no differences could be detected and time from
onset of symptoms associated with EPS to requirement of surgery
was not different between both groups. Therefore this argument is
less convincing than a faster disease process.
The limitations of the study design of course leaves unanswered
questions and room for future studies. The available data from
these two referral centers provided in the registers were limited.
We could not provide more sophisticated information about
membrane function (e.g. osmotic conductance or glucose exposure
during PD) [49]. We were unable to fully comply with suggested
standards for reporting clinical features of EPS as the data was
collected prospectively, before the standards were suggested [50].
Survival was not significantly different between the groups, even so
there was a trend towards a better outcome in the PT-EPS group
(p = 0.3). This does not contradict previous reports, which
demonstrated a better outcome of PT-EPS, as the study was not
powered to find such a difference [19,45]. The younger age of PT-
EPS patients and the better overall condition of patients with a
functioning kidney allograft would be likely explanations for a
better outcome [19].
In conclusion, this analysis did not support the hypothesis that
EPS following transplantation is a different clinico-pathological
entity, despite differences in the time taken between stopping PD
and diagnosis and possible differences in known risk factors such
membrane failure.
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